Literature DB >> 10435210

Cognitive impairment and (CTG)n expansion in myotonic dystrophy patients.

G I Perini1, E Menegazzo, M Ermani, M Zara, A Gemma, E Ferruzza, M Gennarelli, C Angelini.   

Abstract

BACKGROUND: Myotonic dystrophy (DM) is a genetic multisystemic disease with muscular, endocrine, ocular, cardiac and cognitive impairment. The molecular basis of the disease has been identified in an unstable base triplet (CTG)n repeat located in the 3' untranslated region of the miotonin protein-kinase (MT-PK) gene on the long arm of chromosome 19. Cognitive impairment could be a direct expression of this genetic alteration at the central nervous system (CNS) level rather than a consequence of the neuromuscular impairment. To explore this hypothesis, we tested a group of genetically diagnosed, adult onset DM, of their nonaffected relatives (NAR), of patients with spinal muscle atrophy (SMA), and of normal controls using the Wechsler Adult Intelligence Scale (WAIS).
METHODS: Seventeen adult-onset DM patients, 9 NAR, 10 SMA patients and 20 unrelated normal controls (NC) were studied. Clinical, neuromuscular and neuropsychiatric evaluation, which included WAIS and the Schedule for Affective Disorders and Schizophrenia (SADS), were performed on the four groups. DM, NAR and NC were also assessed by a neurophysiological (P300) evaluation. A DNA analysis was performed in DM and in NAR to measure presence and magnitude of CTG expansion.
RESULTS: We found a statistically significant difference between verbal (p < .0003), nonverbal (p < .0001) and total (p < .0001) IQ of DM patients compared to IQs of NAR, SMA and NC. Seven out of 11 WAIS subtests were significantly and consistently lower in DM patients compared to SMA and/or NC. In DM patients there was a statistically significant negative correlation between nonverbal (r = -.68; p < .002) and total (r = .59; p < .01) IQ and (CTG)n. Patients with DM had a significantly lower P300 amplitude compared to NAR and NC.
CONCLUSIONS: Our study indicates that in DM there is a mild but significant cognitive impairment which correlates with the degree of CTG expansion and it is not dependent on the neuromuscular impairment; however further studies with larger groups of patients and controls are suggested to confirm our results, due to the small sample size and to a possible effect of educational level in our patients.

Entities:  

Mesh:

Year:  1999        PMID: 10435210     DOI: 10.1016/s0006-3223(99)00016-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  17 in total

1.  Two children with muscular dystrophies ascertained due to referral for diagnosis of autism.

Authors:  Lonnie Zwaigenbaum; Mark Tarnopolsky
Journal:  J Autism Dev Disord       Date:  2003-04

2.  Endocrine function in 97 patients with myotonic dystrophy type 1.

Authors:  M C Ørngreen; P Arlien-Søborg; M Duno; J M Hertz; J Vissing
Journal:  J Neurol       Date:  2012-02-17       Impact factor: 4.849

3.  Retrospective study on PET-SPECT imaging in a large cohort of myotonic dystrophy type 1 patients.

Authors:  Vincenzo Romeo; E Pegoraro; F Squarzanti; G Sorarù; C Ferrati; M Ermani; P Zucchetta; F Chierichetti; C Angelini
Journal:  Neurol Sci       Date:  2010-09-15       Impact factor: 3.307

4.  How genetics affects the brain to produce higher-level dysfunctions in myotonic dystrophy type 1.

Authors:  Laura Serra; Antonio Petrucci; Barbara Spanò; Mario Torso; Giusy Olivito; Ludovico Lispi; Sandro Costanzi-Porrini; Giovanni Giulietti; Giacomo Koch; Manlio Giacanelli; Carlo Caltagirone; Mara Cercignani; Marco Bozzali
Journal:  Funct Neurol       Date:  2015 Jan-Mar

Review 5.  Clinical and Molecular Spectrum of Muscular Dystrophies (MDs) with Intellectual Disability (ID): a Comprehensive Overview.

Authors:  Malihe Mohamadian; Mandana Rastegar; Negin Pasamanesh; Ata Ghadiri; Pegah Ghandil; Mohsen Naseri
Journal:  J Mol Neurosci       Date:  2021-11-02       Impact factor: 3.444

6.  Cognitive deficits and CTG repeat expansion size in classical myotonic dystrophy type 1 (DM1).

Authors:  Stefan Winblad; Christopher Lindberg; Stefan Hansen
Journal:  Behav Brain Funct       Date:  2006-05-15       Impact factor: 3.759

7.  Comparisons of intellectual capacities between mild and classic adult-onset phenotypes of myotonic dystrophy type 1 (DM1).

Authors:  Stéphane Jean; Louis Richer; Luc Laberge; Jean Mathieu
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

Review 8.  Learning disabilities in neuromuscular disorders: a springboard for adult life.

Authors:  Guja Astrea; Roberta Battini; Sara Lenzi; Silvia Frosini; Silvia Bonetti; Elena Moretti; Silvia Perazza; Filippo M Santorelli; Chiara Pecini
Journal:  Acta Myol       Date:  2016-10

9.  Lack of collagen VI promotes neurodegeneration by impairing autophagy and inducing apoptosis during aging.

Authors:  Matilde Cescon; Peiwen Chen; Silvia Castagnaro; Ilaria Gregorio; Paolo Bonaldo
Journal:  Aging (Albany NY)       Date:  2016-05       Impact factor: 5.682

10.  Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational Study.

Authors:  Celine Dogan; Marie De Antonio; Dalil Hamroun; Hugo Varet; Marianne Fabbro; Felix Rougier; Khadija Amarof; Marie-Christine Arne Bes; Anne-Laure Bedat-Millet; Anthony Behin; Remi Bellance; Françoise Bouhour; Celia Boutte; François Boyer; Emmanuelle Campana-Salort; Françoise Chapon; Pascal Cintas; Claude Desnuelle; Romain Deschamps; Valerie Drouin-Garraud; Xavier Ferrer; Helene Gervais-Bernard; Karima Ghorab; Pascal Laforet; Armelle Magot; Laurent Magy; Dominique Menard; Marie-Christine Minot; Aleksandra Nadaj-Pakleza; Sybille Pellieux; Yann Pereon; Marguerite Preudhomme; Jean Pouget; Sabrina Sacconi; Guilhem Sole; Tanya Stojkovich; Vincent Tiffreau; Andoni Urtizberea; Christophe Vial; Fabien Zagnoli; Gilbert Caranhac; Claude Bourlier; Gerard Riviere; Alain Geille; Romain K Gherardi; Bruno Eymard; Jack Puymirat; Sandrine Katsahian; Guillaume Bassez
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.